Population Health Research Institute
Study List

A Study of the Importance of Conventional and Emerging Risk Factors of Stroke in Different Regions and Ethnic Groups of the World

 < back

To open a new browser window and visit the INTERSTROKE website, please click here.

Stroke is a major public health problem that contributes significantly to the global burden of disease.  It is the most common cause of adult disability and the third leading cause of death worldwide (following coronary heart disease and cancer).  An effective global strategy to reduce the risk of premature stroke mandates systematic evaluation of the contribution of the risk factors in various ethnic groups and geographical locations.  The overall purpose of INTERSTROKE is to learn about the role of known risk factors (e.g. blood pressure) and emerging risk factors (e.g. genetics) for stroke in different regions of the world and ethnic groups.  We will compare risk factors in people with stroke (Cases) to people without stroke (Controls) in a large, international Case-control study that will include approximately 24,000 cases and controls from more than 30 countries.  INTERSTROKE will have enormous implications for our understanding of the causes of stroke worldwide.  It will provide key information to help guide population health initiatives aimed at preventing stroke in low and high-income countries.

Study Design: Observational Study.

Intervention: N/A.

Length of Study: 4 years

# of Patients: 24,000

Patient Populations: Population at risk for stroke.


Available upon study completion.

Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

O'Donnell MJ, Turpie AGG, Johnson J, Turpie I, Kearon C Prevalence of Residual Anticoagulant Activity Following Bridging Low Molecular Weight Heparin. Ann Intern Med. 2007;146(3):184-7.

O'Donnell M, Oczkowski W, Fang J, Kearon C, Kapral M, Silva J, Bradley C, Gould L, D'Uva C, Silver FInfluence of Pre-admission Antithrombotic Therapy on Stroke Severity in Patients with Atrial Fibrillation. Lancet Neurol 2006;5:749-54.

O'Donnell M, Berge E, Sandset PM. Are There Subgroups of Patients with Acute Ischemic Stroke and Atrial Fibrillation that Benefit From Low Molecular Weight Heparin? Stroke 2006;37(2):452-5.

O'Donnell M, Valens N, Lansberg M, Wijman C. Is Thyroid Replacement Therapy a Risk Factor for Ischemic Stroke with Atrial Fibrillation? Neurology.2006;67(9): 1714-6.

Hirsh J, O'Donnell M, Weitz JI New Anticoagulants. Blood. 2005;105(2):453-63.

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca